Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database

Abstract

Objective This study aimed to compare clinical features and overall survival (OS) between patients with primary peritoneal serous carcinoma (PPSC) and those with advanced serous ovarian carcinoma (ASOC) and to identify prognostic factors. Methods Patients diagnosed with PPSC and ASOC from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were enrolled. Pearson’s chi-square test was used to compare clinical features. The primary endpoint was OS. The Kaplan–Meier method and log–rank test were used to perform the survival analysis. Propensity score matching was also conducted. Univariate, multivariate and subgroup analyses were performed using the Cox proportional hazards model. Results A total of 708 PPSC patients and 7610 ASOC patients were enrolled. The clinical features of PPSC patients were noticeably different from those of ASOC patients. The survival analysis showed that PPSC patients had poorer outcomes than ASOC patients. Even after the clinical features were balanced, PPSC patients still had poorer survival. Univariate and multivariate analyses indicated that older age, higher tumor grade and advanced American Joint Committee on Cancer stage were adverse prognostic factors in both groups, while surgery and chemotherapy were protective factors. A subgroup analysis demonstrated that most factors favored ASOC patients. The total distant metastasis rates of PPSC and ASOC were similar. Liver or lung metastasis was common, but bone and brain metastases were rare. A higher proportion of liver metastasis was observed in the ASOC group. Conclusion The clinical features and survival outcomes between PPSC patients and ASOC patients are clearly different, and PPSC is more aggressive than ASOC.

Nomogram incorporating log odds of positive lymph nodes improves prognostic prediction for ovarian serous carcinoma: a real-world retrospective cohort study

“…The training cohort (n=2935) was used to screen variables, establish the predictive model and develop the nomogram, while the validation cohort (n=1257) was used to validate the results of the training cohort. The potential predictors derived from the previous forecasting study in literature 17 18. Both cohorts included the same variables selected from SEER: age (<50, 50–70 and >70), ethnicity, marital status, tumour size, grade, laterality, surgery type, T stage in the eighth edition AJCC system, M stage in the eighth edition AJCC system, radiotherapy, chemotherapy and LODDS.…”

Unravelling Peritoneal Carcinomatosis Using Cross-Sectional Imaging Modalities

“…Primary Peritoneal Serous Carcinoma-Figure S15 It occurs in women, predominantly postmenopausal, and is challenging to diagnose as it resembles advanced epithelial ovarian carcinoma (AEOC), both in imaging and in the histological exam. It occurs less frequently than AEOC and has a worse prognosis [66]. The distinguishing features are the sparing of the ovaries or the disproportionate burden of extra-ovarian disease compared to the ovarian involvement [67].…”

Carcinoma primario peritoneal sincrónico con tumor de músculo liso de potencial maligno incierto: reporte de caso

“…Las neoplasias peritoneales se pueden clasificar según el sitio de origen como primarias o secundarias, las primarias son raras y dentro de ellas se encuentra el CSP, cuya incidencia es aproximadamente de 6,78 casos por cada 1 000 000 de personas en Estados Unidos; sin embargo, se desconoce la tasa de incidencia mundial (1,2) . Este es un tumor epitelial maligno, histológicamente indistinguible del carcinoma seroso de ovario o del mesotelioma peritoneal (3)(4)(5), que afecta principalmente a mujeres añosas (3) y se presenta como "carcinomatosis peritoneal", siendo el diagnóstico incidental en la laparotomía exploratoria por otras causas, encontrando generalmente enfermedad avanzada (2,6,7) .…”

“…Instituto Regional de Enfermedades Neoplásicas Norte, Trujillo, Perú. 3 Departamento de Cirugía Oncológica. Instituto Regional de Enfermedades Neoplásicas Norte, Trujillo, Perú.…”